Jefferies Global Healthcare Conference
Logotype for Scholar Rock Holding Corp

Scholar Rock (SRRK) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Scholar Rock Holding Corp

Jefferies Global Healthcare Conference summary

17 Nov, 2026

U.S. approval and launch

  • FDA approved ISEMBYLD on Sept. 11, 2026, as the first muscle-targeted SMA therapy; U.S. launch is underway for patients age 2+ receiving ongoing SMN2-targeted treatment.

  • Global reach ambition covers 35,000–40,000 patients receiving an SMN-targeted therapy, across up to 50 countries.

  • In the first six weeks through October, treatment-naive enrollment forms exceeded forms for patients transitioning from early access or long-term extension programs.

  • More than one-third of the top 140 U.S. SMA treatment centers submitted enrollment forms; demand was geographically broad and steady week to week.

  • Enrollees included children and a substantial number of adults, varied background SMN therapies, and improving, plateaued, or declining motor-function trajectories.

Access and commercial outlook

  • Anthem and Centene published medical policies aligned with the FDA label; the two payers cover 47 million commercial lives.

  • Intent-to-treat to first infusion averages 60–90 days at launch; a drug-specific J-code is expected April 1, 2027, after the required two-quarter wait following September filing.

  • Conversion time is expected to move toward 2–3 weeks over the year after approval as J-code, formularies, and medical policies are established; expected conversion rate is 85% or more.

  • Most enrolled patients were expected to receive first infusion in early 2027; disclosures will track center reach, demand, conversion, payer coverage, and revenue.

  • Estimated net annual price is ~$310,000; WAC is $11,659 per vial, with a gross price near $450,000 based on ~3 vials per infusion and 13 annual infusions. Medicaid, 340B discounts, and infusion frequency affect net price.

Ex-U.S. expansion

  • EMA validated the resubmitted MAA; CHMP opinion is expected in H1 2027, with a Germany launch expected later in 2027, followed by country-level pricing and reimbursement agreements.

  • Japan’s JNDA was filed two months ahead of guidance and accepted for priority review; PMDA typically targets a nine-month review, with launch opportunity next year.

  • The targeted global population is already receiving SMN-targeted therapy in countries with rare-disease reimbursement; those therapies represent a $5B+ annual market, with 64% of revenues outside the U.S.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Scholar Rock